Abstract
Embelin is a natural product, inhibitor of XIAP (X-chromosome-linked Inhibitor of APoptosis) with strong proapoptotic properties on cancer cells. In order to clarify the role of two OH groups on benzoquinone core, we have prepared by hemisynthesis close analogs of embelin, where these OH groups have been replaced in a systematic manner by OMe and OAc groups. Proapoptotic activities of six embelin derivatives have been studied as single agent, or in combination with TRAIL, and their abilities to interact with XIAP have been evaluated by Surface Plasmon Biacore. Our results show that these new embelin analogs have good proapoptotic properties against selected cancer cells, often higher than the natural product itself. Further, this activity is not directly mediated by XIAP. Altogether these preliminary results demonstrate that for active embelin analogs, the two OH groups are not absolutely required for anticancer activity, opening new possibilities for the design of proapoptotic derivatives in these series.
Keywords: Apoptosis, Cancer, Embelin, Hemisynthesis, Natural Products, XIAP.
Medicinal Chemistry
Title:Hemisynthesis of Selected Embelin Analogs and Investigation of their Proapoptotic Activity Against Cancer Cells
Volume: 9 Issue: 8
Author(s): Guillaume Viault, Katragadda Suresh Babu, Fabien Gautier, Sophie Barillé-Nion, Philippe Juin, Olivier Tasseau and René Grée
Affiliation:
Keywords: Apoptosis, Cancer, Embelin, Hemisynthesis, Natural Products, XIAP.
Abstract: Embelin is a natural product, inhibitor of XIAP (X-chromosome-linked Inhibitor of APoptosis) with strong proapoptotic properties on cancer cells. In order to clarify the role of two OH groups on benzoquinone core, we have prepared by hemisynthesis close analogs of embelin, where these OH groups have been replaced in a systematic manner by OMe and OAc groups. Proapoptotic activities of six embelin derivatives have been studied as single agent, or in combination with TRAIL, and their abilities to interact with XIAP have been evaluated by Surface Plasmon Biacore. Our results show that these new embelin analogs have good proapoptotic properties against selected cancer cells, often higher than the natural product itself. Further, this activity is not directly mediated by XIAP. Altogether these preliminary results demonstrate that for active embelin analogs, the two OH groups are not absolutely required for anticancer activity, opening new possibilities for the design of proapoptotic derivatives in these series.
Export Options
About this article
Cite this article as:
Viault Guillaume, Babu Suresh Katragadda, Gautier Fabien, Barillé-Nion Sophie, Juin Philippe, Tasseau Olivier and Grée René, Hemisynthesis of Selected Embelin Analogs and Investigation of their Proapoptotic Activity Against Cancer Cells, Medicinal Chemistry 2013; 9 (8) . https://dx.doi.org/10.2174/1573406411309080003
DOI https://dx.doi.org/10.2174/1573406411309080003 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Biomolecules in Medicinal and Pharmaceutical Chemistry for Drug Development
Medicinal chemists play a vital role in the drug development process by identifying and synthesizing molecules that define structure-activity correlations and ensure efficacy and safety in preclinical animal testing. The fields of medicinal chemistry and pharmaceutical chemistry constitute an analogy that has the potential to encourage a beneficial relationship between ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Uptake and Organ Accumulation of Amphipolar Metallocorroles with Cytoprotective and Cytotoxic Properties
Anti-Cancer Agents in Medicinal Chemistry Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Current Alzheimer Research Development of 96-microwell Plate Assay with Fluorescence Reader and HPLC Method with Fluorescence Detection for High-throughput Analysis of Linifanib in its Bulk and Dosage Forms
Current Pharmaceutical Analysis Alpha-Crystallins and Tumorigenesis
Current Molecular Medicine Medulloblastoma: Role of Developmental Pathways, DNA Repair Signaling, and Other Players
Current Molecular Medicine Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives
Current Medicinal Chemistry Using the Neurosphere Assay to Quantify Neural Stem Cells In Vivo
Current Pharmaceutical Biotechnology Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
Current Pharmaceutical Biotechnology P2Y Receptor Activation Affects the Proliferation and Differentiation of Glial and Neuronal Cells: A Focus on Rat C6 Glioma Cells
Current Neuropharmacology Experimental Therapy for Lung Cancer: Umbilical Cord-Derived Mesenchymal Stem Cell-Mediated Interleukin-24 Delivery
Current Cancer Drug Targets Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Current Pharmaceutical Design Current Understanding of Epigenetics Driven Therapeutic Strategies in Colorectal Cancer Management
Endocrine, Metabolic & Immune Disorders - Drug Targets ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design p53: A Guide to Apoptosis
Current Cancer Drug Targets HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets